Cargando…

Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users

AIMS: This study aimed to compare the rates of major cardiovascular adverse events in sodium‐glucose cotransporter‐2 inhibitors (SGLT2I) and dipeptidyl peptidase‐4 inhibitors (DPP4I) users in a Chinese population. SGLT2I and DPP4I are increasingly prescribed for type 2 diabetes mellitus patients. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jiandong, Lee, Sharen, Leung, Keith Sai Kit, Wai, Abraham Ka Chung, Liu, Tong, Liu, Ying, Chang, Dong, Wong, Wing Tak, Wong, Ian Chi Kei, Cheung, Bernard Man Yung, Zhang, Qingpeng, Tse, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934922/ https://www.ncbi.nlm.nih.gov/pubmed/35132823 http://dx.doi.org/10.1002/ehf2.13830

Ejemplares similares

Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong
por: Lee, Sharen, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
por: Mui, Jonathan V., et al.
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new‐onset overall cancer in Type 2 diabetes mellitus: A population‐based study
por: Chung, Cheuk To, et al.
Publicado: (2023)

Development of a predictive risk model for all-cause mortality in patients with diabetes in Hong Kong
por: Lee, Sharen, et al.
Publicado: (2021)

Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong
por: Mui, Jonathan V., et al.
Publicado: (2023)

Low rates of liver injury in edoxaban users: Evidence from a territory‐wide observational cohort study
por: Zhou, Jiandong, et al.
Publicado: (2021)

Development of an Electronic Frailty Index for Predicting Mortality and Complications Analysis in Pulmonary Hypertension Using Random Survival Forest Model
por: Zhou, Jiandong, et al.
Publicado: (2022)

Predictive value of neutrophil‐to‐lymphocyte ratio for atrial fibrillation and stroke in type 2 diabetes mellitus: The Hong Kong Diabetes Study
por: Chang, Carlin, et al.
Publicado: (2022)

Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study
por: Zhou, Jiandong, et al.
Publicado: (2021)

Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong
por: Zhou, Jiandong, et al.
Publicado: (2021)

Author Correction: Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong
por: Zhou, Jiandong, et al.
Publicado: (2022)

Gender- and Age-Specific Associations of Visit-to-Visit Blood Pressure Variability With Anxiety
por: Zhou, Jiandong, et al.
Publicado: (2021)

Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning
por: Lee, Sharen, et al.
Publicado: (2021)

Predictive scores for identifying patients with type 2 diabetes mellitus at risk of acute myocardial infarction and sudden cardiac death
por: Lee, Sharen, et al.
Publicado: (2021)

Combined effect of sodium–glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors for diabetic kidney disease
por: Araki, Shin‐ichi
Publicado: (2019)

Paediatric/young versus adult patients with long QT syndrome
por: Lee, Sharen, et al.
Publicado: (2021)

Territory-wide cohort study of Brugada syndrome in Hong Kong: predictors of long-term outcomes using random survival forests and non-negative matrix factorisation
por: Lee, Sharen, et al.
Publicado: (2021)

Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong
por: Au, Philip C. M., et al.
Publicado: (2023)

Measures of repolarization variability predict ventricular arrhythmogenesis in heptanol-treated Langendorff-perfused mouse hearts
por: Tse, Gary, et al.
Publicado: (2021)

Comparisons of the risk of myopericarditis between COVID-19 patients and individuals receiving COVID-19 vaccines: a population-based study
por: Chou, Oscar Hou In, et al.
Publicado: (2022)

P-Wave Area Predicts New Onset Atrial Fibrillation in Mitral Stenosis: A Machine Learning Approach
por: Tse, Gary, et al.
Publicado: (2020)

Territory-Wide Chinese Cohort of Long QT Syndrome: Random Survival Forest and Cox Analyses
por: Tse, Gary, et al.
Publicado: (2021)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis
por: Zhou, Jiandong, et al.
Publicado: (2022)

Clinical characteristics, risk factors and outcomes of cancer patients with COVID‐19: A population‐based study
por: Zhou, Jiandong, et al.
Publicado: (2022)

Outcomes in Brugada Syndrome Patients With Implantable Cardioverter-Defibrillators: Insights From the SGLT2 Registry
por: Lee, Sharen, et al.
Publicado: (2020)

Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
por: Shaheer, Abid, et al.
Publicado: (2021)

Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
por: Bae, Jaehyun, et al.
Publicado: (2022)

Risk of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wide Retrospective Cohort Study
por: Ng, Pauline Yeung, et al.
Publicado: (2023)

The Impact of Cardiac Comorbidity Sequence at Baseline and Mortality Risk in Type 2 Diabetes Mellitus: A Retrospective Population-Based Cohort Study
por: Lee, Sharen, et al.
Publicado: (2022)

Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor
por: Lee, Hsin-Fu, et al.
Publicado: (2020)

Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis
por: Min, Se Hee, et al.
Publicado: (2018)

Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized
por: Wood, Stephen J, et al.
Publicado: (2022)

Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
por: Foresta, Andreana, et al.
Publicado: (2023)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Multi‐modality machine learning approach for risk stratification in heart failure with left ventricular ejection fraction ≤ 45%
por: Tse, Gary, et al.
Publicado: (2020)

Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
por: Shao, Shih-Chieh, et al.
Publicado: (2020)

Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study
por: Chung, Yoo-Ri, et al.
Publicado: (2019)

Evolutionary Analysis of Dipeptidyl Peptidase I
por: Varda, Nina, et al.
Publicado: (2022)

Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
por: Lee, Hsin-Fu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lqt2t6jc7ric8o9cmih74sij83